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Kleine–Levin syndrome (KLS) is an episodic hypersomnia with cognitive disturbances such
as confusion, apathy, and derealization. Hyperphagia and hypersexuality occur in around
50% of cases. No evidence-based treatments have been established for KLS. Many drugs
have been tried, most often with little success. Here, a case with a striking response to
lithium is presented.
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INTRODUCTION
Kleine–Levin syndrome (KLS) is classified as a periodic hyper-
somnia. Diagnostic criteria have been put forward (Table 1)
(1). Episodic hypersomnia and cognitive disturbances constitute
the core abnormalities. Although hyperphagia and hypersexual-
ity were originally thought to be the cardinal symptoms of KLS,
they are only present in around 50% of cases. Recent studies have
suggested that recurrent hypersomnia and at least one of the fol-
lowing symptoms: confusion, apathy, or derealization, constitute
improved criteria (Table 1).
Unfortunately no evidence-based treatments have been estab-
lished for KLS. Many drugs have been tried, mostly with little
success. Possibly lithium has shown the most effect or around
40% (2). Here, a case with a dramatic response to lithium is pre-
sented. Why lithium might have an effect in this treatment resistant
disorder is briefly discussed.
CASE
A former healthy 19-year-old male began suffering from 1 to 2-
week long episodes (with regular 4–5 week intervals) where he was
without any energy and could not attend school or do his daily
routines. During the episodes he had difficulty in concentrating,
slowness of thought, decreased short time memory, reduced physi-
cal energy, and feeling of derealization. He described himself being
like a zombie or in an unreal state. The patient was examined by
a psychiatrist both during and between the episodes, which did
not reveal any psychiatric disorder. There was no history of drug
abuse.
Besides sleeping during the episodes he could at best watch a
simple television program. He became extremely irritable when
his parents pressed him to do anything. He spent most of his time
in his bedroom and slept for 14–20 h/day for 1–2 weeks. During
the episodes, he preferred to be in the dark and avoided communi-
cation with other people, even his best friends. Interestingly, he had
almost no memory of the episodes. Between the episodes, he was
perfectly normal, attending school without difficulty, and playing
golf at a high level. During the episodes, his parents had to wake
him up to give him food. He went self to the bathroom, but other-
wise he stayed in bed. The attacks started relatively quickly, under
a few hours and resided under a few hours. During the attacks
he did not eat excessively and there were no signs of hypersexu-
ality. No relative has suffered from a similar condition. Extensive
psychiatric examination did not reveal any signs of psychiatric dis-
ease or depression. There were no signs of epilepsy. Somatic and
neurologic examination was normal. Magnetic resonance imag-
ing was normal. Extensive blood tests were normal. EEG showed
some hypoactivity in the frontal-lobes, but no signs of epilepsy.
At first, lamotrigine was titrated up to 100 mg twice daily and
maintained for a few months without any effect. After 2 years his
treatment was changed to lithium and serum levels kept between
0.6 and 0.9 mmol/l. Since then he has not had an attack for 3 years.
He tolerates the medication well and has not wanted to stop the
treatment.
DISCUSSION
Kleine–Levin syndrome is considered a rare disorder (no
population-based studies are available). The cardinal symptom
in KLS is recurrent episodes of hypersomnia. Other symptoms
such as cognitive affection, hyperphagia, and hypersexuality are
observed in various degrees (1). The disorder is somewhat more
common in males (63%) and starts during adolescence and young
adulthood (2). The cause of KLS is unknown. Intermittent hypo-
thalamic dysfunction seems likely, but there is only limited evi-
dence for this. Postmortem studies are rare because the condition
is not fatal. Microglial infiltrations in the thalamus and midbrian
as well as decreased pigmentation in the substantia nigra have been
described (3).
Hypersomnia, which is the cardinal symptom of the disorder, is
compulsory for diagnosis. An exemplary episode starts relatively
quickly within a few hours, where the observers see the patient
become increasingly tired, often after a trigger such as infec-
tion alcohol intake or head trauma (3). During the episodes, the
patient usually sleeps between 12 and 24 h/day. The patient in the
case above did not have symptoms of hypersexuality/hyperphagia.
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Table 1 | Diagnostic criteria for recurrent hypersomnia and
Kleine–Levin syndrome (1).
• Patient experiences recurrent episodes of excessive sleepiness lasting
for 2 days to 4weeks
• Episodes recur at least once per year
• Alertness, cognitive function, and behavior are normal between episodes
and hypersomnia is not better explained by another sleep, medical,
neurological, mental disorder, medication use, or substance abuse
In addition to all recurrent hypersomnia criteria, the patient should also
have at least one of the following
• Cognitive abnormalities – e.g., derealization, confusion, and
hallucinations
• Abnormal behavior – e.g., irritability, aggression, or uncharacteristic
behavior
• Hyperphagia
• Hypersexuality
Possibly too much weight has been laid on those symptoms, con-
ceivably leading to under diagnosis of KLS. On the other hand,
cognitive difficulties such as memory defects, confusion, attention,
and concentration are always present. Patients describe a state of
mental viscosity/slowness and derealization or feeling “strange,”
“detached,” or “different” is very common. As in our patient, many
patients have anterograde amnesia of the episodes.
In all cases, brain computerized tomography and magnetic
resonance imaging are normal. Studies performed in the midst
and between the episodes with SPECT, PET, and perfusion MRI
have shown hypoperfusion in the frontal-lobe, temporal-lobe,
and hypothalamic areas (3). On the one hand, cognitive distur-
bances and derealization could be explained by temporal-lobe
dysfunction. On the other hand, apathy and disinhibition could
be explained by frontal-lobe dysfunction. Thalamus and hypo-
thalamus involvement, which have been frequent findings, could
explain hypersomnia or apparent sleeplike behavior. Interestingly,
hypoperfusion has been shown to be present in 50% of the patients
in the temporal-lobe during asymptomatic periods (3). Hypop-
erfusion in the frontal-lobe and the basal ganglia has also been
found (3). This suggests that certain subclinical abnormalities are
present between the attacks. This also leads to the question of
abnormalities after KLS has gone into remission. A low-frequency
high-amplitude wave (delta or theta) mainly in the bilateral tem-
poral or temporofrontal area and a non-specific frontal slowing of
background activity is often seen on the EEG. This parallels the
SPECT findings.
Many medications have been tried in KLS, most without suc-
cess. Stimulants have been tested. Amphetamines significantly
reduce sleepiness in patients, but unfortunately they do not
improve and can even make the more troublesome behavioral and
cognitive disturbances worse. In the largest review on KLS (108
patients) only lithium showed an effect significantly higher than
no treatment (OR 3.8, P = 0.02) (2).
Lithium had a dramatic effect on the patient above. Interest-
ingly, lithium has also an effect on cluster headache, a periodic
disorder that might have its origin in the hypothalamus, like KLS.
Lithium is most known for its effect in bipolar disorder, which is a
disorder of periodicity, like KLS. Lithium up-regulates glutamate
reuptake. Hence, it decreases glutamate availability at synapses.
This might have an anti-manic effect since gluatmate is an exci-
tatory neurotransmitter. It is of course unknown, if through this
mechanism it exerts its effect on KLS (4).
Even today, little is known about lithium’s mechanism of action
despite being known and used for over 40 years in bipolar disor-
ders. The drug has a number of hypothetical mechanisms, which
will not be elaborated here, but it induces a shortage of inositol in
the brain. This causes a deficiency of substrate for phosphatidyli-
nositol resynthesis, but solely in overactive neurons (5), which
might clarify lithium’s effect with minimal effects on normal
behavior (6).
Firstly, since the patient did not have symptoms of overeating
or hypersexuality one can only claim that lithium had a striking
effect on the recurrence of hypersomnia and this possible thera-
peutic effect should be investigated more deeply. Secondly, KLS,
cluster headache, and bipolar disorders, all seem to respond to
lithium? This should be looked in to more closely. Thirdly, on the
cellular level, what is the reason for lithium’s observed effect in
KLS? Is it through a shortage of inositiol with a secondary possi-
ble dampening on overactive neurons or is it through decreased
glutamate availability at synapses or is there an alternative expla-
nation. This should be studied further. After observing this case
and taking into account larger case series, lithium should without
a doubt be tried as a therapeutic option for KLS.
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